CLINICAL TRIALS PROFILE FOR ERBITUX

All Clinical Trials for ERBITUX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	Greenwich Hospital	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	Indiana University	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	IUPUI, Indianapolis, IN	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	University of Colorado, Denver	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	Eli Lilly and Company	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00034541 ↗	Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer	Completed	ImClone LLC	Phase 1/Phase 2	2000-12-01	The study will enroll approximately 33 EGFr positive chemotherapy-naive stage IV non-small cell lung cancer patients. Patients will receive cetuximab in combination with carboplatin and paclitaxel for two cycles or until disease progression or until the patient exhibits intolerable toxicities. Patients will be evaluated for efficacy and safety throughout the duration of the study.
NCT00042939 ↗	Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2003-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with cetuximab may kill more tumor cells. PURPOSE: This randomized phase II trial is studying giving irinotecan and docetaxel together with cetuximab to see how well it works compared to irinotecan and docetaxel alone in treating patients with metastatic pancreatic cancer .

Clinical Trial Conditions for ERBITUX

Condition Name

Condition Name for ERBITUX
Intervention	Trials
Colorectal Cancer	46
Head and Neck Cancer	40
Metastatic Colorectal Cancer	30
Squamous Cell Carcinoma of the Head and Neck	14

Condition MeSH

Condition MeSH for ERBITUX
Intervention	Trials
Colorectal Neoplasms	106
Head and Neck Neoplasms	89
Carcinoma, Squamous Cell	78
Carcinoma	74

Clinical Trial Locations for ERBITUX

Trials by Country

Trials by Country for ERBITUX
Location	Trials
China	53
Italy	51
Canada	51
France	34
Japan	33

Trials by US State

Trials by US State for ERBITUX
Location	Trials
Texas	76
California	66
New York	57
Pennsylvania	57
Florida	53

Clinical Trial Progress for ERBITUX

Clinical Trial Phase

Clinical Trial Phase for ERBITUX
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	34
Phase 2/Phase 3	10

Clinical Trial Status

Clinical Trial Status for ERBITUX
Clinical Trial Phase	Trials
Completed	161
Terminated	57
Recruiting	52

Clinical Trial Sponsors for ERBITUX

Sponsor Name

Sponsor Name for ERBITUX
Sponsor	Trials
National Cancer Institute (NCI)	54
Bristol-Myers Squibb	46
Eli Lilly and Company	41

Sponsor Type

Sponsor Type for ERBITUX
Sponsor	Trials
Other	371
Industry	287
NIH	57